JNJ

186.79

+0.34%↑

ABT

125.77

+1.66%↑

TMO

565.15

+0.26%↑

ISRG

538.71

-0.99%↓

DHR

213.79

-0.14%↓

JNJ

186.79

+0.34%↑

ABT

125.77

+1.66%↑

TMO

565.15

+0.26%↑

ISRG

538.71

-0.99%↓

DHR

213.79

-0.14%↓

JNJ

186.79

+0.34%↑

ABT

125.77

+1.66%↑

TMO

565.15

+0.26%↑

ISRG

538.71

-0.99%↓

DHR

213.79

-0.14%↓

JNJ

186.79

+0.34%↑

ABT

125.77

+1.66%↑

TMO

565.15

+0.26%↑

ISRG

538.71

-0.99%↓

DHR

213.79

-0.14%↓

JNJ

186.79

+0.34%↑

ABT

125.77

+1.66%↑

TMO

565.15

+0.26%↑

ISRG

538.71

-0.99%↓

DHR

213.79

-0.14%↓

Search

Pfizer

Închisă

SectorSănătate

24.31 -1.58

Rezumat

Modificarea prețului

24h

Curent

Minim

24.2

Maxim

25.19

Indicatori cheie

By Trading Economics

Venit

-45M

2.9B

Vânzări

938M

15B

P/E

Medie Sector

13.106

37.003

EPS

0.78

Randament dividend

6.87

Marjă de profit

19.982

Angajați

81,000

EBITDA

266M

5.3B

Recomandări

By TipRanks

Recomandări

Neutru

Prognoză pe 12 luni

+15.98% upside

Dividende

By Dow Jones

Randament dividend

Medie Sector

6.87%

2.25%

Data viitoare de dividende

1 dec. 2025

Următoarea dată ex-dividende

7 nov. 2025

Statistici piață

By TradingEconomics

Capitalizare de piață

7.1B

141B

Deschiderea anterioară

25.89

Închiderea anterioară

24.31

Sentimentul știrilor

By Acuity

52%

48%

298 / 373 Clasament în Healthcare

Scor tehnic

By Trading Central

Încredere

Bullish Evidence

Pfizer Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

4 nov. 2025, 12:29 UTC

Câștiguri
Achiziții, Fuziuni, Preluări

Pfizer 3Q Profit Falls Amid Lower Covid-19 Drug Demand -- Update

4 nov. 2025, 12:12 UTC

Câștiguri

Pfizer 3Q Profit Falls Amid Lower Covid-19 Drug Demand

4 nov. 2025, 22:10 UTC

Achiziții, Fuziuni, Preluări

Pfizer, Novo Nordisk Escalate Bidding War for Weight-Loss Drug Startup -- 2nd Update

4 nov. 2025, 19:39 UTC

Achiziții, Fuziuni, Preluări

Pfizer, Novo Nordisk Escalate Bidding War for Weight-Loss Drug Startup -- Update

4 nov. 2025, 18:35 UTC

Achiziții, Fuziuni, Preluări

Novo Nordisk Is Still Beating Pfizer in Battle Over Metsera -- Barrons.com

4 nov. 2025, 18:11 UTC

Câștiguri

Pfizer 3Q Profit Falls Amid Lower Covid-19 Drug Demand -- 2nd Update

4 nov. 2025, 17:59 UTC

Câștiguri

Pfizer Stock Slips. Under the Surface, Earnings Weren't Great. -- Barrons.com

4 nov. 2025, 17:26 UTC

Achiziții, Fuziuni, Preluări

Novo Nordisk Is Still Beating Pfizer in Battle Over Metsera -- Barrons.com

4 nov. 2025, 16:01 UTC

Achiziții, Fuziuni, Preluări

Pfizer, Novo Nordisk Escalate Bidding War for Weight-Loss Drug Startup -- WSJ

4 nov. 2025, 15:17 UTC

Achiziții, Fuziuni, Preluări

Novo Nordisk and Pfizer Sweeten Their Offers for Weight-Loss Drug Startup Metsera -- WSJ

4 nov. 2025, 14:58 UTC

Achiziții, Fuziuni, Preluări

Novo Nordisk Sweetens Offer for Metsera -- WSJ

4 nov. 2025, 14:37 UTC

Achiziții, Fuziuni, Preluări

Novo Nordisk: Proposal Is Subject to Terms of Pfizer's Merger Pact With Metsera

4 nov. 2025, 14:35 UTC

Achiziții, Fuziuni, Preluări

Novo Nordisk Says Offer Highlights Commitment to Investing in U.S., Interest in Growing Scale of U.S. Investments

4 nov. 2025, 14:34 UTC

Achiziții, Fuziuni, Preluări

Novo Nordisk Believes Proposal, Including Structure, Complies With Applicable Laws and Is in Best Interest of Patients

4 nov. 2025, 14:33 UTC

Achiziții, Fuziuni, Preluări

Novo Nordisk Offers $62.20 a Share in Cash and Up to $24 a Share Based on Certain Milestones

4 nov. 2025, 14:32 UTC

Achiziții, Fuziuni, Preluări

Novo Nordisk Confirms Updated Bid For Metsera

4 nov. 2025, 14:12 UTC

Achiziții, Fuziuni, Preluări

Metsera Says Pfizer Merger Agreement Remains in Effect >MTSR

4 nov. 2025, 14:12 UTC

Achiziții, Fuziuni, Preluări

Metsera, Pfizer May Negotiate Potential Adjustments for Two Business Days >MTSR

4 nov. 2025, 14:12 UTC

Achiziții, Fuziuni, Preluări

Metsera: Novo Nordisk Offer Superior to Revised Pfizer Proposal That Valued It at Up to $ 70/Shr, a Total of About $8.1B >MTSR

4 nov. 2025, 14:11 UTC

Achiziții, Fuziuni, Preluări

Metsera: Novo Nordisk's Amended Proposal Values It at Up to $ 86.20/Shr, a Total of About $ 10.0B >MTSR

4 nov. 2025, 14:10 UTC

Achiziții, Fuziuni, Preluări

Metsera Receives Amended Proposal From Novo Nordisk; Metsera Declares Novo Nordisk Amended Proposal 'Superior'

4 nov. 2025, 12:37 UTC

Câștiguri
Achiziții, Fuziuni, Preluări

Pfizer Stock Slips on Third-Quarter Earnings. What Covid-19 Has to Do With It. -- Barrons.com

4 nov. 2025, 12:02 UTC

Câștiguri

Pfizer Stock Rises on Third-Quarter Earnings. Here's Why. -- Barrons.com

4 nov. 2025, 11:49 UTC

Câștiguri

Pfizer: On Track to Deliver $7.2B Net Cost Savings From Cost-Improvement Initiatives by End 2027 >PFE

4 nov. 2025, 11:47 UTC

Câștiguri

Pfizer: Expect to Continue to De-Lever in Prudent Manner to Maintain Balanced Capital-Allocation Strategy >PFE

4 nov. 2025, 11:47 UTC

Câștiguri

Pfizer: Current Financial Guidance Doesn't Anticipate Any Share Buybacks in 2025 >PFE

4 nov. 2025, 11:46 UTC

Câștiguri

Pfizer: 2025 Guidance Absorbs Impact of Currently Imposed Tariffs From China, Canada, Mexico >PFE

4 nov. 2025, 11:46 UTC

Câștiguri

Pfizer Backs 2025 View of Rev $61B-$64B >PFE

4 nov. 2025, 11:45 UTC

Câștiguri

Pfizer Had Seen 2025 Adjusted EPS $2.90-$3.10 >PFE

4 nov. 2025, 11:45 UTC

Câștiguri

Pfizer 3Q Rev $16.65B >PFE

Comparație

Modificare preț

Pfizer Așteptări

Obiectiv de preț

By TipRanks

15.98% sus

Prognoză pe 12 luni

Medie 28.6 USD  15.98%

Maxim 34 USD

Minim 24 USD

În baza a 17 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruPfizer - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Neutru

17 ratings

4

Cumpărare

12

Păstrare

1

Vânzare

Scor tehnic

By Trading Central

22.855 / 23.85Suport & Rezistență

Termen scurt

Bullish Evidence

Termen mediu

Bearish Evidence

Termen lung

Bearish Evidence

Sentiment

By Acuity

298 / 373 Clasament în Sănătate

Sentimentul știrilor

Evidențe de scădere

Volatilitate

Sub medie

Volumul știrilor (RCV)

Peste medie

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Pfizer

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE, as well as has strategic clinical collaboration with Acepodia Inc. for the development of antibody-cell conjugation-based cell therapies in autoimmune diseases. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
help-icon Live chat